Harmonix Management, a venture capital investment firm focused on investments in science-driven startups, has launched fundraising for its third fund, which will will continue the firm’s strategy of focusing on healthcare, life sciences, and deep tech investments.
Harmonix Management, a venture capital investment firm focused on investments in science-driven startups, has launched fundraising for its third fund (Fund III) which will will continue the firm’s strategy of focusing on healthcare, life sciences, and deep tech investments.
The launch of fundraising for Fund III marks a significant milestone in the Firm’s ability to identify portfolio companies that have collectively yielded ten major breakthroughs across biotech and medtech that stand to affect over one billion patients.
Harmonix’s diverse portfolio, which totals over $40 million in assets under management, features a range of cutting-edge companies, including Bit.Bio, a platform programming the software of life; Volumetric, a 3D bio-printing platform for drug research and human organ replacements; and Insilico Medicine, an AI drug discovery and development platform.
The Firm also continues to harness the multidisciplinary expertise of its personnel and advisory board members across healthcare, life sciences, and deep tech to deploy investments that encourage collaboration and impactful breakthroughs.
Additionally, Harmonix believes it is well-positioned to identify investments in artificial intelligence and machine learning that are driving many of the firm’s portfolio companies.
